We investigated the feasibility of using radioiodine therapy in colon carcinoma cells (HCT 116) following tumor-specific expression of the human sodium iodide symporter (hNIS) using the carcinoembryonic antigen (CEA) promoter. HCT 116 cells were stably transfected with an expression vector, in which hNIS cDNA has been coupled to a CEA promoter fragment. This promoter is responsible for tissue-specific expression of CEA in gastrointestinal tract epithelium, and has been shown to target therapeutic genes to colorectal cancer cells. Functional NIS expression was confirmed by iodide uptake assay, Western blot analysis, immunostaining and in vitro clonogenic assay. The stably transfected HCT 116 cells concentrated 125 I about 10-fold in vitro without evidence of iodide organification. In contrast, transfection of control cancer cells without CEA expression did not result in iodide accumulation. Western blot analysis using a hNISspecific antibody revealed a band of approximately 90 kDa.
I about 10-fold in vitro without evidence of iodide organification. In contrast, transfection of control cancer cells without CEA expression did not result in iodide accumulation. Western blot analysis using a hNISspecific antibody revealed a band of approximately 90 kDa.
In addition, immunostaining of stably transfected HCT 116 cells revealed hNIS-specific membrane-associated immunoreactivity. In an in vitro clonogenic assay approximately 95% of stably transfected HCT 116 cells were killed by exposure to 131 I, while only about 5% of NIS-negative control cells were killed. Further, using an adenovirus carrying the NIS gene linked to the CEA promoter, high levels of tumorspecific radioiodide accumulation were induced in HCT 116 cells. In conclusion, a therapeutic effect of
Introduction
The sodium iodide symporter (NIS), an intrinsic membrane glycoprotein with 13 putative transmembrane domains, mediates the active uptake of one iodide ion along with two sodium ions across the basolateral membrane of benign and malignant thyroidal cells. [1] [2] [3] [4] The unique property of thyroid follicular cells to trap and concentrate iodide due to expression of NIS allows diagnostic imaging as well as highly effective therapy of differentiated thyroid carcinomas and their metastases by administration of radioiodine. 5 Differentiated thyroid carcinomas including papillary and follicular carcinomas are treated by total thyroidectomy followed by 131 I ablation of the thyroid remnant and occult microscopic local and distant residual disease. Therapy with 131 I has been successfully used for over 40 years in the treatment of differentiated thyroid cancer, improving the prognosis of thyroid cancer patients significantly, and making thyroid cancer one of the most manageable cancers. 5 Cloning of the human and rat NIS genes in 1996 and their extensive characterization have not only revolutionized our understanding of the physiology and pathophysiology of thyroidal iodide accumulation but also provided us with a powerful new diagnostic and therapeutic gene. Expression of functional NIS in cancer cells enables these cells to concentrate iodide from plasma, and therefore offers the possibility of diagnostic and therapeutic application of radioiodine. NIS gene transfer followed by radioiodine therapy therefore represents a novel cytoreductive gene therapy strategy extending the extensive experience with radioiodine in the management of differentiated thyroid cancer to the treatment of nonthyroidal cancer. [2] [3] [4] 6 NIS further represents a therapeutic gene that is associated with a bystander effect, because not only NIS-transduced cancer cells but also surrounding nontransduced cells are destroyed by the crossfire effect of the b-emitter 131 I, that is characterized by a path length of 0.2-2.4 mm. 7 Since in vivo transduction efficiency is limited by low levels of vector delivery to tumor cells and by the toxicity of available vector systems, application of therapeutic genes with a significant bystander effect is highly desirable because it offers the prospect of killing neighbouring untransfected tumor cells. 7 Moreover, use of tissue-specific promoters provides a way of selectively targeting the NIS gene to tumor cells, thereby maximizing tissue-or tumor-specific radioiodine accumulation and associated cytotoxicity with minimal nonspecific iodide uptake and radiation-induced toxic side effects in other organs. 8 In recent studies, we investigated the feasibility of radioiodine therapy in prostate cancer following prostate-specific antigen (PSA) promoter-driven NIS gene transfer. The androgen-sensitive human prostatic adenocarcinoma cell line LNCaP stably transfected with the human NIS gene under the control of a 6 kb-PSApromoter fragment revealed androgen-dependent and prostate-specific iodide uptake activity, which was sufficient to allow a therapeutic response of accumulated 131 I in vitro in a clonogenic assay as well as in vivo in xenografts in nude mice.
9,10 A highly significant therapeutic effect of 131 I has also been demonstrated in LNCaP cell xenografts following in vivo NIS gene delivery using an adenovirus carrying the human NIS gene linked to the CMV promoter (Ad5-CMV-NIS).
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Encouraged by these data in prostate cancer cells, in the current study we chose colon cancer as an important, distinct tumor model to investigate the potential of the NIS gene as a novel therapeutic gene. To achieve tumorspecificity we applied the carcinoembryonic antigen (CEA) promoter to drive NIS expression in colon cancer cells. The CEA promoter is responsible for specific expression of CEA in gastrointestinal tract epithelium, and has been shown to target therapeutic genes to colorectal cancer cells expressing high levels of CEA.
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Results
Iodide accumulation studies following transient and stable transfection with hNIS cDNA 
Western blot analysis
Following stable transfection with CEA/NIS-pGL3 (CN-1) and CEA-pGL3 (C-1), respectively, NIS protein expression was determined in HCT 116 cells by Western blot analysis (Figure 4 ). Western blotting of membrane proteins derived from CN-1 cells using a mouse monoclonal antibody that recognizes the carboxy-terminus of hNIS, revealed a band of a molecular weight of approximately 90 kDa (lane 1), which was not detected in C-1 cells (lane 2).
Immunocytochemical staining
Using a highly sensitive immunostaining technique and a mouse monoclonal hNIS-specific antibody, distinct, primarily membrane-associated (arrows) NIS-specific immunoreactivity was detected in CN-1 cells ( 
Discussion
Colorectal cancer is a common disease in Western society, ranking second to lung cancer in men and breast cancer in women as a cause of cancer-related mortality. The mainstay of therapy is surgical resection, which is often unsatisfactory due to advanced, recurrent and metastatic disease. Application of adjuvant chemotherapy or chemo-radiation in patients with a high risk of recurrent disease has shown only a limited survival advantage. 17 Despite advances in diagnosis and therapy, the 5-year survival rate for colon cancer has not improved over the last decade; therefore, new therapeutic approaches, including gene therapeutic strategies, are urgently needed. The data presented here may open a new avenue for colon cancer by gene therapy. A variety of gene therapy strategies for colon cancer have been examined in recent years, such as corrective gene therapy aiming at restoration of mutated p53 tumor suppressor gene or inactivation of the K-ras oncogene, immunomodulatory gene therapy including cytokine gene transfer, costimulation with B7, vaccination against the CEA, and cytoreductive gene therapy, using the herpes simplex virus thymidine kinase/ganciclovir system, the cytosine deaminase/5-fluorocytosine system and the nitroreductase/CB1954 system. 18 However, none of these therapeutic approaches has reached the clinical arena yet.
In contrast, treatment of thyroid cancer by radioactive iodine taking advantage of endogenous expression of NIS represents an effective standard therapy. Targeted expression of the NIS gene followed by radioiodine therapy therefore represents a novel cytoreductive gene therapy strategy for the treatment of extrathyroidal malignancies. [2] [3] [4] 6 Several investigators explored the ability of NIS gene transfer to induce radioiodine accumulation in nonthyroidal tumor cells. Using various gene delivery techniques, including electroporation, liposomes and viral vectors, radioiodine accumulation was induced in vitro and in vivo in various cancer cell lines by NIS gene delivery. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] To achieve the ultimate goals of cancer therapy, which are maximal tissue-or tumor-specific cytotoxicity with a minimum of toxic effects in nonmalignant cells, as well as elimination of metastatic cancer cells in addition to the local tumor, tissue-or tumor-specific targeting of therapeutic genes is desirable. Besides the possibility of surface targeting by viral vector envelope modification or modification of the viral backbone to generate viral vectors that selectively replicate in tumor cells, the application of tissue-or tumor-specific promoters provides a well-established way of transcriptionally targeting of therapeutic genes selectively to cancer cells. 8 In an earlier study we explored the efficacy of NIS gene transfer to induce accumulation as well as a therapeutic effect of 131 I in stably transfected prostate cancer cells, 9,10 using the PSA promoter to target NIS gene expression to prostate cells. 8, [31] [32] [33] Prostate cellspecific iodide uptake activity was induced and shown to be sufficiently high to selectively kill NIS-transfected LNCaP cells in vitro as well as in vivo in LNCaP cell xenografts. [9] [10] [11] These studies clearly showed for the first time that tissue-specific NIS gene delivery into nonthyroidal tumors is capable of inducing the accumulation of therapeutically effective radioiodine doses in vitro and in vivo, and might therefore represent an effective and potentially curative therapy for extrathyroidal tumors.
In the present study we used a tumor-specific promoter, the CEA promoter, to target NIS gene transfer to colon cancer cells. The CEA is a glycoprotein of 180 000 Da expressed on the cell surface of gastrointestinal tract epithelial cells. 34 Although CEA is also expressed in normal colon, the expression levels are much higher in colon cancer and other cancers of epithelial cell origin. CEA has therefore been widely used as a marker of tumors of epithelial cell origin, in particular colon cancer and others, such as stomach, pancreas, lung, ovary and breast cancers. 35 As the CEA promoter is responsible for specific expression of CEA in cancers of epithelial cell origin, in particular gastrointestinal tract epithelial cells, it represents an ideal means for tumor-specific gene delivery in colon cancer. Cloning and characterization of the CEA gene have shown that the 403 nucleotides upstream of the translation initiation site contains the sequence responsible for tissue-specific expression of the CEA gene. [35] [36] [37] [38] [39] In a variety of studies, this CEA promoter fragment has been shown to be able to target therapeutic genes to colorectal cancer cells expressing high levels of CEA. [12] [13] [14] [15] [16] Using this CEA promoter fragment, we were able to target hNIS expression to human colon cancer cells resulting in tumor-specific radioiodide accumulation. Functional NIS expression was specific for CEA expressing colon cancer cells as evidenced by lack of iodide uptake activity in control cancer cells without CEA expression. In addition, HCT 116 cell lines stably expressing NIS under the control of the CEA promoter concentrated 125 I about 10-fold, which is approximately half of the iodide uptake activity induced in LNCaP cells stably transfected with NIS under the control of the PSA promoter in our recent studies. 9 Iodide efflux out of NIStransfected HCT 116 cells was comparable to iodide efflux out of LNCaP cells stably expressing NIS under the control of the PSA promoter. 9, 10 Despite the quite rapid iodide efflux rate, the amount of accumulated 10 This difference in 131 I cytotoxicity may result from a higher radiation sensitivity of colon cancer cells compared to prostate cancer cells.
As a next crucial step towards in vivo application of CEA promoter-driven NIS gene transfer followed by radioiodine therapy in colon cancer, we developed a replication-deficient recombinant human adenovirus serotype 5 carrying the human NIS gene linked to the 11 and was only about 20% less than the level of radioiodine accumulation that could be reached in HCT 116 cells using Ad5-CMV-NIS, which drives NIS expression by the strong viral CMV promoter widely used for high expression of therapeutic genes. In an earlier study we have used Ad5-CMV-NIS for NIS gene delivery in prostate cancer xenografts, which resulted in a highly significant therapeutic effect of 131 I.
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Ad5-CEA-NIS-mediated NIS gene delivery in colon cancer cells therefore was tumor-specific and highly efficient. Tissue-or tumor-specific promoters tend to be weaker than viral promoters, which is often a concern regarding transduction efficiency that has to be sufficiently high to allow a therapeutic effect. In the case of the CEA promoter, our data show that promoter activity is high and comparable to CMV promoter activity. The magnitude of tumor-specific radioiodide accumulation in colon cancer cells following Ad5-CEA-NIS-mediated NIS gene transfer is very encouraging and a therapeutic effect of 131 I can therefore be expected in vivo, which will be investigated in future studies.
The radiation dose responsible for a possible therapeutic effect of trapped radioiodine is determined by the rate of uptake of iodide and its retention time in the tumor cell, which is affected by rate of iodide efflux, the rate of radioactive decay, iodide recirculation and iodide binding to cellular proteins or lipids, a process termed iodide organification. Although no iodide organification was detected in colon cancer cells in our present study and iodide efflux was quite rapid, the amount of accumulated 131 I was highly effective in preventing the formation of cell clones in an in vitro clonogenic assay. Considering that in vivo in three-dimensional tumors, recirculation of iodide is possible between iodide accumulating cells surrounded by other iodide accumulating and iodide releasing cells resulting in enhanced iodide retention in tumors, the therapeutic efficacy of 131 I is expected to be even higher in vivo than in vitro. This hypothesis has been supported by our recent data in LNCaP cells following PSA promoter-driven NIS gene transfer. Although iodide was rapidly released into the medium in vitro, in vivo in LNCaP cell xenografts, the average biological half-life for radioiodine was long enough to allow a dramatic therapeutic effect of 131 I with an average tumor volume reduction of more than 85%. 10, 11 In addition to recirculation of iodide in vivo, the crossfire effect of 131 I b particles has been demonstrated to be more prominent in three-dimensional tumors, where complete absorption of b energy is possible than in cell monolayers in vitro, where only a small portion of the b energy is deposited in the cell monolayer. 26, 40 In conclusion, a therapeutic effect of 131 I has been demonstrated in colon cancer cells following induction of tumor-specific iodide uptake activity by CEA promoter-directed NIS expression in vitro. This study demonstrates the potential of NIS as a therapeutic gene allowing radioiodine therapy of colon cancer following tumor-specific NIS gene transfer, provided that further studies will confirm radioiodine accumulation and therapeutic efficacy of 131 I in the in vivo situation.
Materials and methods
Cell culture
The human colon cancer cell line HCT 116 and control cancer cell lines Tel-CEB6 (human osteosarcoma cells) and T98G (human glioblastoma multiforme cells) were grown in DMEM medium, and LNCaP cells (human prostatic adenocarcinoma cells) were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (Life Technologies, Inc., Karlsruhe, Germany) and penicillin G (2 U/ml)/streptomycin sulfate (100 mg/ml) (Life Technologies). Cells were maintained in a 5% CO 2 -95% air atmosphere at 371C with a change of medium every third day and passaged every 7 days using 0.05% trypsin (Life Technologies).
Plasmid constructs
The full-length NIS cDNA was removed from the pcDNA3 expression vector (kindly provided by Dr SM Jhiang, Ohio State University, Columbus, OH, USA) by restriction digestion using XbaI and HindIII, agarose-gel purified and ligated into the vector pGL3-Basic (Promega, Mannheim, Germany). Following restriction digestion with KpnI and HindIII of NIS-pGL3, a 365 bp fragment of the promoter of the CEA (kindly provided by Dr P Searle, University of Birmingham, UK) was ligated into NIS-pGL3. The resulting plasmid construct containing full-length NIS cDNA coupled to the CEA promoter (CEA/NIS-pGL3) was agarose-gel purified and confirmed by DNA sequencing. A control vector was designed containing the CEA promoter fragment without the NIS cDNA (CEA-pGL3).
Transient transfection
The human colon cancer cell line HCT 116 and control cancer cell lines Tel-CEB6 and LNCaP were used in transfection experiments. Prior to transfections, cells were grown to a 50-70% confluency and transfected with CEA/NIS-pGL3 or the control vector CEA/pGL3, using LipofectAMINE Plus Reagent (Life Technologies) under serum-free conditions according to the manufacturer's recommendations. Following transfections, cells were incubated for 48 h in growth medium. All groups of cells were prepared in triplicate for transfections, which were performed at least three times.
Stable transfection
HCT 116 cells were co-transfected with CEA/NIS-pGL3 or the control vector CEA/pGL3, respectively, and a plasmid containing a puromycin resistance cassette (pBabePuro) (1/20 of the applied concentration of CEA/NIS-pGL3 or CEA/pGL3) using LipofectAMINE Plus Reagent under serum-free conditions as described above. Selection was performed with 1.25 mg/ml puromycin (Sigma, Taufkirchen, Germany) in DMEM medium containing 10% FBS for approximately 3 weeks from the day after transfection. Surviving clones were isolated and subjected to screening for iodide uptake activity. Five stably transfected cell lines termed CN-1, -2, -3, -4 and -5 (CEA/NIS-pGL3) that showed highest levels 
Iodide uptake studies
Uptake of 125 I by transfected colon cancer cells and control cancer cell lines was determined at steady-state conditions as described by Weiss et al. 41 In brief, cells were plated on six-or 12-well plates (10 5 cells/ml) and following transfections, iodide uptake studies were performed in Hank's balanced salt solution (HBSS) supplemented with 10 mM NaI, 0.1 mCi Na 125 I/ml and 10 mM HEPES at pH 7.3. A measure of 100 mM KClO 4 was added to control wells (final concentration: 10 mM). Following incubation for 45 min, trapped iodide was removed from cells by a 20-min incubation in 1 N NaOH and measured by g-counting.
Measurement of iodide organification
Cells, grown in six-well plates, were incubated for 2 h at 371C with HBSS supplemented with 10 mM NaI, 0.1 mCi Na 125 I/ml and 10 mM HEPES at pH 7.3. Contents of organified iodide in the cells were determined by trichloroacetic acid (TCA) precipitation as described by Urabe et al.
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Iodide efflux studies 
Membrane preparation
Following transfections, cell membranes were prepared from HCT 116 cells by a modification of a previously described procedure. 43 In brief, cells plated on 100-mm dishes were washed with PBS, harvested and resuspended in buffer A, consisting of 250 mM sucrose, 10 mM HEPES pH 7.5, 1 mM EDTA, 10 mg/ml leupeptin, 10 mg/ ml aprotinin and 1 mM phenylmethanesulfonyl fluoride (PMSF). The homogenate was centrifuged twice at 500g for 15 min at 41C. Following centrifugations, 100 ml 1 M Na 2 CO 3 /ml buffer A was added to the supernatant and incubated at 41C for 45 min with continuous shaking. Then, a further centrifugation at 100 000g was performed for 15 min and the pellet was resuspended in an appropriate volume of buffer B consisting of 250 mM sucrose, 10 mM HEPES pH 7.5 and 1 mM MgCl 2 . Protein concentrations were determined by a protein assay (Biorad DC Protein Assay, Biorad, Munich, Germany).
Western blot analysis
For Western blot analysis, the NuPAGE electrophoresis system (NOVEX, San Diego, CA, USA) was used. Aliquots of membranes (20 mg) prepared from transfected HCT 116 cells were reduced by incubation with 0.5 M DTT for 10 min at 701C and loaded on 4-12% BisTris-HCl buffered polyacrylamide gels. Following gel electrophoresis for 1 h, proteins were transferred onto nitrocellulose membranes using electroblotting. Following blotting, membranes were preincubated for 1 h in 5% low-fat dried milk in TBS-T (20 mM Tris, 137 mM NaCl and 0.1% Tween-20) to block nonspecific binding sites. Membranes were then incubated with a mouse monoclonal antibody directed against amino-acid residues 468-643 of human NIS (dilution 1:3000) 44 for 2 h at room temperature. After washing with TBS-T, horseradish peroxidase-labelled goat-anti-mouse-antibody was applied (dilution 1:5000) for 1 h at room temperature prior to incubation with ECL Western blotting detection reagents (Amersham, Braunschweig, Germany) for 1 min. Exposures were made at room temperature for approximately 1 min using Kodak BIOMAX MR films. Prestained protein molecular weight standards (Life Technologies) were run in the same gels for comparison of molecular weight and estimation of transfer efficiency.
Immunocytochemical staining
Immunocytochemical staining was performed using the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA). Stably transfected HCT 116 cells were plated directly onto one-chamber slides and grown to 60% confluency. Monolayers were washed with PBS, airdried overnight and incubated at 401C for 45 min. Cells were then rehydrated in PBS, and preincubated for 20 min with blocking serum to inhibit nonspecific binding. Cell monolayers were then incubated with the mouse monoclonal antibody mentioned above at a dilution of 1:2400 for 90 min at room temperature. Cell monolayers were washed and incubated with biotinconjugated anti-mouse-immunoglobulin for 30 min at room temperature, followed by incubation with preformed avidin and biotinylated horseradish peroxidase macromolecular complex. Diaminobenzidine (DAB) was used as the chromogen, and yielded a bluish-black precipitate indicative of hNIS-specific immunoreactivity. Slides were counterstained with malachite green for 5 min prior to mounting. Parallel monolayers with the primary and secondary antibodies replaced in turn by PBS and isotype matched nonimmune IgGs were examined to assure specificity, and to exclude crossreactivities between the antibodies and conjugates employed.
In vitro clonogenic assay
Cells were grown to 50% confluency and incubated for 7 h with 0.1 mCi/ml Na 131 I (total dose 0.8 mCi (29.6 MBq)) in HBSS supplemented with 10 mM NaI and 10 mM HEPES at pH 7.3. Following incubation with radioiodine, cells were washed with HBSS, trypsinized and plated at cell densities of 2000, 4000 and 6000 cells/ well (six wells each) in 12-well plates. After 4 weeks, after cell colony development, cells were fixed with methanol and stained with crystal violet, and colonies containing 450 cells were counted. Parallel experiments were performed for each cell line using HBSS without 131 I, and all values were adjusted for plating efficiency. The percentage of survival represents the percentage of cell colonies after 131 I treatment compared with mock treatment with HBSS.
Recombinant adenovirus production
Replication-deficient human recombinant type 5 adenovirus (Ad5) carrying the human NIS gene linked to the Expression of sodium iodide symporter in colon cancer cells IV Scholz et al CMV promoter (Ad5-CMV-NIS) or CEA promoter (Ad5-CEA-NIS) were developed in collaboration with the Gene Transfer Vector Core Facility of the University of Iowa (Iowa City, IA, USA) and ViraQuest (North Liberty, IA, USA), respectively. Ad5-CMV-NIS carrying hNIS cDNA under the control of the CMV promoter was developed as described previously. 11 For generation of Ad5-CEA-NIS, the human NIS cDNA was ligated into pAd5kNpA (using HindIII and NotI) and linked to the CEA promoter fragment (using XhoI and HindIII). The resulting plasmid was co-transfected into 293 cells with near full-length adenoviral DNA previously restricted to remove a portion of the E1 region. Following transfection, plaques were harvested and lysates prepared by three rounds of freeze/thawing. Lysates were then used to infect 100 mm plates of 293 cells. After complete cytopathic effect, cells were harvested, lysed by freeze/ thawing and functional analysis was performed by measurement of iodide uptake in transfected HCT 116 cells (see above). Following two more rounds of plaque purification the resulting recombinant adenovirus (Ad5-CEA-NIS) was expanded in 293 cells and purified by banding on CsCl density gradients, followed by dialysis.
Adenovirus-mediated NIS gene delivery in vitro
Cells plated on six-or 12-well plates (1 Â 10 5 cells/ml) were washed and incubated with OptiMEM (Life Technologies) containing Ad5-CMV-NIS or Ad5-CEA-NIS (MOI ¼ 20-80) for 3 h. Medium was replaced by fresh culture medium and virus-infected cells were further maintained for 4 days, before iodide accumulation was measured to determine levels of functional NIS protein expression (see above).
Statistical methods
All experiments were carried out in triplicates or quadruplicates. For the clonogenic assay, six wells were evaluated for each condition and cell density. Results are presented as means7s.e.m. Statistical significance was tested using Student's t-test, ANOVA or Mann-Whitney rank sum test. Results shown are representative of three experiments performed under the same conditions.
